Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid

Abstract excerpt

The recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to interferon and immune responses
• Share to SARS-CoV-2 and COVID-19 Research
• Share to vaccines and immunoinformatics approaches